Quantitative Susceptibility Mapping of Time-Dependent Susceptibility Changes in Multiple Sclerosis Lesions

REFERENCES

1. 1.↵
   2. de Rochefort L,
   3. Liu T,
   4. Kressler B, et al

   . Quantitative susceptibility map reconstruction from MR phase data using Bayesian regularization: validation and application to brain imaging. Magn Reson Med 2010;63:194–206 doi:10.1002/mrm.22187 pmid:19953507

   CrossRefPubMed
2. 2.↵
   2. Wang Y,
   3. Spincemaille P,
   4. Liu Z, et al

   . Clinical quantitative susceptibility mapping (QSM): biometal imaging and its emerging roles in patient care. J Magn Reson Imaging 2017;46:951–71 doi:10.1002/jmri.25693 pmid:28295954

   CrossRefPubMed
3. 3.↵
   2. Langkammer C,
   3. Liu T,
   4. Khalil M, et al

   . Quantitative susceptibility mapping in multiple sclerosis. Radiology 2013;267:551–59 doi:10.1148/radiol.12120707 pmid:23315661

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Stuber C,
   3. Pitt D,
   4. Wang Y

   . Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping. Int J Mol Sci 2016;17 doi:10.3390/ijms17010100 pmid:26784172

   CrossRefPubMed
5. 5.↵
   2. Wisnieff C,
   3. Ramanan S,
   4. Olesik J, et al

   . Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: interpreting positive susceptibility and the presence of iron. Magn Reson Med 2015;74:564–70 doi:10.1002/mrm.25420 pmid:25137340

   CrossRefPubMed
6. 6.↵
   2. Filippi M,
   3. Rocca MA,
   4. Ciccarelli O, et al

   ; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303 doi:10.1016/S1474-4422(15)00393-2 pmid:26822746

   CrossRefPubMed
7. 7.↵
   2. Absinta M,
   3. Sati P,
   4. Schindler M, et al

   . Persistent 7-Tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016;126:2597–609 doi:10.1172/JCI86198 pmid:27270171

   CrossRefPubMed
8. 8.↵
   2. Yao Y,
   3. Nguyen TD,
   4. Pandya S, et al

   . Combining quantitative susceptibility mapping with automatic zero reference (QSM0) and myelin water fraction imaging to quantify iron-related myelin damage in chronic active MS lesions. AJNR Am J Neuroradiol 2018;39:303–10 doi:10.3174/ajnr.A5482 pmid:29242359

   Abstract/FREE Full Text
9. 9.↵
   2. Li JQ,
   3. Chang SX,
   4. Liu T, et al

   . Reducing the object orientation dependence of susceptibility effects in gradient echo MRI through quantitative susceptibility mapping. Magn Reson Med 2012;68:1563–69 doi:10.1002/mrm.24135 pmid:22851199

   CrossRefPubMed
10. 10.↵
    2. Zhou D,
    3. Liu T,
    4. Spincemaille P, et al

    . Background field removal by solving the Laplacian boundary value problem. NMR Biomed 2014;27:312–19 doi:10.1002/nbm.3064 pmid:24395595

    CrossRefPubMed
11. 11.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM). J Magn Reson Imaging 2016;44:426–32 doi:10.1002/jmri.25144 pmid:26800367

    CrossRefPubMed
12. 12.↵
    2. Zhang Y,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping and R2* measured changes during white matter lesion development in multiple sclerosis: myelin breakdown, myelin debris degradation and removal, and iron accumulation. AJNR Am J Neuroradiol 2016;37:1629–35 doi:10.3174/ajnr.A4825 pmid:27256856

    Abstract/FREE Full Text
13. 13.↵
    2. Zhang S,
    3. Nguyen TD,
    4. Zhao Y, et al

    . Diagnostic accuracy of semiautomatic lesion detection plus quantitative susceptibility mapping in the identification of new and enhancing multiple sclerosis lesions. Neuroimage Clin 2018;18:143–48 doi:10.1016/j.nicl.2018.01.013 pmid:29387531

    CrossRefPubMed
14. 14.↵
    2. Chen W,
    3. Gauthier SA,
    4. Gupta A, et al

    . Quantitative susceptibility mapping of multiple sclerosis lesions at various ages. Radiology 2014;271:183–92 doi:10.1148/radiol.13130353 pmid:24475808

    CrossRefPubMed
15. 15.↵
    2. Bagnato F,
    3. Hametner S,
    4. Yao B, et al

    . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134(Pt 12):3602–15 doi:10.1093/brain/awr278 pmid:22171355

    CrossRefPubMed
16. 16.↵
    2. Yao B,
    3. Ikonomidou VN,
    4. Cantor FK, et al

    . Heterogeneity of multiple sclerosis white matter lesions detected with T2*-weighted imaging at 7.0 Tesla. J Neuroimaging 2015;25:799–806 doi:10.1111/jon.12193 pmid:25657078

    CrossRefPubMed
17. 17.↵
    2. Dal-Bianco A,
    3. Grabner G,
    4. Kronnerwetter C, et al

    . Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017;133:25–42 doi:10.1007/s00401-016-1636-z pmid:27796537

    CrossRefPubMed
18. 18.↵
    2. Kaunzner UW,
    3. Kang Y,
    4. Zhang S, et al

    . Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain 2019;142:133–45 doi:10.1093/brain/awy296 pmid:30561514

    CrossRefPubMed
19. 19.↵
    2. Deh K,
    3. Kawaji K,
    4. Bulk M, et al

    . Multicenter reproducibility of quantitative susceptibility mapping in a gadolinium phantom using MEDI+0 automatic zero referencing. Magn Reson Med 2019;81:1229–36 doi:10.1002/mrm.27410 pmid:30284727

    CrossRefPubMed
20. 20.↵
    2. Deh K,
    3. Nguyen TD,
    4. Eskreis-Winkler S, et al

    . Reproducibility of quantitative susceptibility mapping in the brain at two field strengths from two vendors. J Magn Reson Imaging 2015;42:1592–600 doi:10.1002/jmri.24943 pmid:25960320

    CrossRefPubMed
21. 21.↵
    2. Liu Z,
    3. Spincemaille P,
    4. Yao Y, et al

    . MEDI+0: morphology enabled dipole inversion with automatic uniform cerebrospinal fluid zero reference for quantitative susceptibility mapping. Magn Reson Med 2018;79:2795–803 doi:10.1002/mrm.26946 pmid:29023982

    CrossRefPubMed
22. 22.↵
    2. Jenkinson M,
    3. Bannister P,
    4. Brady M, et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 doi:10.1006/nimg.2002.1132 pmid:12377157

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Gaitán MI,
    3. Shea CD,
    4. Evangelou IE, et al

    . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22–29 doi:10.1002/ana.22472 pmid:21710622

    CrossRefPubMed
24. 24.↵
    2. Deh K,
    3. Ponath GD,
    4. Molvi Z, et al

    . Magnetic susceptibility increases as diamagnetic molecules breakdown: myelin digestion during multiple sclerosis lesion formation contributes to increase on QSM. J Magn Reson Imaging 2018;48:1281–87 doi:10.1002/jmri.25997 pmid:29517817

    CrossRefPubMed
25. 25.↵
    2. Kuhlmann T,
    3. Ludwin S,
    4. Prat A, et al

    . An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol 2017;133:13–24 doi:10.1007/s00401-016-1653-y pmid:27988845

    CrossRefPubMed
26. 26.↵
    2. Frischer JM,
    3. Bramow S,
    4. Dal-Bianco A, et al

    . The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175–89 doi:10.1093/brain/awp070 pmid:19339255

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Prineas JW,
    3. Kwon EE,
    4. Cho ES, et al

    . Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646–57 doi:10.1002/ana.1255 pmid:11706971

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Singh S,
    3. Dallenga T,
    4. Winkler A, et al

    . Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. J Neuroinflammation 2017;14:57 doi:10.1186/s12974-017-0831-8 pmid:28302146

    CrossRefPubMed
29. 29.↵
    2. Stephenson E,
    3. Nathoo N,
    4. Mahjoub Y, et al

    . Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014;10:459–68 doi:10.1038/nrneurol.2014.118 pmid:25002107

    CrossRefPubMed
30. 30.↵
    2. Mehta V,
    3. Pei W,
    4. Yang G, et al

    . Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013;8:e57573 doi:10.1371/journal.pone.0057573 pmid:23516409

    CrossRefPubMed
31. 31.↵
    2. Hametner S,
    3. Wimmer I,
    4. Haider L, et al

    . Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013;74:848–61 doi:10.1002/ana.23974 pmid:23868451

    CrossRefPubMed
32. 32.↵
    2. Lassmann H

    . The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563–76 doi:10.1016/j.nic.2008.06.005 pmid:19068402

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Maggi P,
    3. Absinta M,
    4. Grammatico M, et al

    . Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 2018;83:283–94 doi:10.1002/ana.25146 pmid:29328521

    CrossRefPubMed
34. 34.↵
    2. Nguyen TD,
    3. Deh K,
    4. Monohan E, et al

    . Feasibility and reproducibility of whole brain myelin water mapping in 4 minutes using fast acquisition with spiral trajectory and adiabatic T2prep (FAST-T2) at 3 Tesla. Magn Reson Med 2016;76:456–65 doi:10.1002/mrm.25877 pmid:26331978

    CrossRefPubMed
35. 35.↵
    2. Magliozzi R,
    3. Reynolds R,
    4. Calabrese M

    . MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course. Brain Pathol 2018;28:735–42 doi:10.1111/bpa.12642 pmid:30020563

    CrossRefPubMed
36. 36.↵
    2. Bian W,
    3. Tranvinh E,
    4. Tourdias T, et al

    . In vivo 7T MR quantitative susceptibility mapping reveals opposite susceptibility contrast between cortical and white matter lesions in multiple sclerosis. AJNR Am J Neuroradiol 2016;37:1808–15 doi:10.3174/ajnr.A4830 pmid:27282860

    Abstract/FREE Full Text